Table 2.
The different monoclonal antibodies (mAbs) in various stages of research and development to neutralize the coronavirus.
Antibody name | Source | Organization | Study type | Target | Reference |
---|---|---|---|---|---|
REGN3048/REGN3051 | Humanized mouse | Regeneron | Mouse/NHP efficacy | RBD | (Pascal et al. 2015) |
G2, G4, D12, F11, | S/S1 immunized mouse | NIH NIAID | NHP efficacy | S1, S2, RBD | (Wang et al. 2015) |
2E6, 4C2 | RBD immunized mice | Chinese Academy of Sciences | Mouse efficacy | RBD | (Li et al. 2015) |
LCA60 | Human survivor | HUMABS BioMed | Mouse/NHP efficacy | RBD | (Corti et al. 2015) |
3B11 (AV-3) | Human antibody library | Dana-Farber Cancer Institute and AbViro LLC | NHP efficacy | RBD | (Tang et al. 2014) |
m336, m337, m338 | Human antibody library | NIH National Cancer Institute | In vitro | RBD | (Xia et al. 2014) |